Ekso Bionics® Unveils its Latest Assistive Exoskeleton Innovation for Industrial Use
August 20 2020 - 8:30AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today unveiled EVOTM, an endurance-boosting
assistive upper body exoskeleton that alleviates the burden of
repetitive work. Building on the Company’s trailblazing EksoVest
technology, EVO’s innovative design is the next step in the
evolution of industrial exoskeletons.
Through collaborations with leaders in global manufacturing and
construction, Ekso Bionics has accumulated a wealth of in-the-field
customer insights that allowed it to reimagine its weight-assist
exoskeleton technology. EVO is lighter and more flexible than its
predecessor, with an optimized human-machine interface that is cool
and comfortable to wear for all-day use, while also maintaining the
ruggedness and durability that Ekso is known for. EVO’s novel
design also incorporates Ekso’s new patented low profile,
multi-link structure, which tracks the natural movement of the body
and allows for an unrestricted range of motion, and a device
architecture that is compatible with standard safety harnesses used
in elevated work. These advancements in design make EVO the ideal
solution for a wide range of industrial, manufacturing, food
processing, and construction applications.
“Through working closely with our customers, we gained
tremendous insights and feedback that help us evolve EVO to better
meet their needs and provide a programmatic solution to some of
their most complicated ergonomic problems,” said Michael Pratt,
vice president at Ekso Bionics. “By augmenting human capabilities,
EVO was designed to relieve the burden on industrial workers and
provide them with a technology solution that improves their quality
of life. True to our mission, we are now offering a flexible
acquisition model that will lower the capital barrier and allow
more industrial workers access to the latest exoskeleton
technology.”
Shoulder injuries caused by overhead work, repetitive tasks, and
overexertion is the leading cause of lost work days due to
workplace injuries. Ekso Bionics is striving to alleviate the
burden on skilled workers, drastically reducing the number of
workplace injuries and cutting down on worker fatigue.
EVO is a passive, spring-loaded assistive upper-body exoskeleton
that aids workers with overhead work. It is designed to reduce
fatigue and shoulder and back muscle strain, with the goal of
eliminating work-related injuries to the neck, shoulder, and back.
EVO offers 5-15 pounds of lift assistance in each arm to elevate
and alleviate the day-to-day strain on workers across all
industries.
For more information on EVO, please visit our website at
www.eksobionics.com and request a virtual demonstration.
About Ekso Bionics® Ekso Bionics® is
a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical and industrial applications. Founded in
2005, the Company continues to build upon its industry-leading
expertise to design some of the most cutting-edge, innovative
wearable robots available on the market. Ekso Bionics is the only
exoskeleton company to offer technologies that range from helping
those with paralysis to stand up and walk, to enhancing human
capabilities on job sites across the globe. The Company is
headquartered in the San Francisco Bay Area and is listed on the
Nasdaq Capital Market under the symbol “EKSO.” For more
information,
visit: www.eksobionics.com or follow
@EksoBionics on Twitter.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding he
potential benefits, performance and effectiveness of the Company’s
products and systems, including EVO. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company’s current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company’s inability to obtain adequate financing or
maintain operating revenues (including as a result of the COVID-19
pandemic) to fund the Company’s operations and necessary to develop
or enhance the Company’s technology, the significant length of time
and resources associated with the development of the Company’s
products, the Company’s failure to achieve broad market acceptance
of the Company’s products, the failure of the Company’s sales and
marketing efforts or of partners to market the Company’s products
effectively, adverse results in future clinical studies of the
Company’s medical device products, the failure to obtain or
maintain patent protection for the Company’s technology, the
failure of the Company to obtain or maintain regulatory approval to
market the Company’s medical devices, disruptions in the Company’s
supply chain due to the outbreak of the COVID-19 virus and other
delays that may result from the COVID-19 pandemic, the Company’s
lack of product diversification, existing or increased competition,
and the Company’s failure to implement the Company’s business plans
or strategies. These and other factors are identified and described
in more detail in the Company’s filings with the U.S. Securities
and Exchange Commission. To learn more about Ekso Bionics please
visit the Company’s website at www.eksobionics.com or follow
@EksoBionics on Twitter. The Company does not undertake to update
these forward-looking statements.
Media Contact: Carrie Yamond Mas 917-371-2320
cmas@eksobionics.com
Investor Contact: David Carey 212-867-1768
investors@eksobionics.com
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/a83bd57f-ea8f-4b37-a4bd-a530fe891de8https://www.globenewswire.com/NewsRoom/AttachmentNg/83960b98-aea4-432f-a3c6-0c79fd0f5831
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/abddabd9-a97c-4cf8-9e4e-bacc65fb622b. The
photo is also available at Newscom, www.newscom.com, and via
AP PhotoExpress.
A video accompanying this announcement is available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/92c2c7b9-dac1-4034-b7a0-1f091cdaff19
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024